MarketCapExport financials
Dynatronics Corporation (DYNT)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Dynatronics Corporation Financial Statements 2025-2010 | DYNT
Annual Financial Statements Dynatronics Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
1.95 M | 821 K | 2.71 M | 2 M | - | 9.24 M | 12.9 M | 18.9 M | 8.35 M | 7.55 M | 7.86 M | 10.5 M | 5.96 M | 6.28 M | 20.3 M | - |
Shares |
8.13 M | 3.42 M | 3.87 M | 3.57 M | 17.4 M | 10.3 M | 8.25 M | 6.62 M | 3.15 M | 2.71 M | 2.52 M | 2.52 M | 2.53 M | 2.56 M | 2.67 M | - |
Historical Prices |
0.24 | 0.24 | 0.7 | 0.56 | 0.73 | 1.51 | 1.92 | 2.15 | 2.65 | 2.8 | 2.84 | 3.49 | 3.63 | 2.57 | 4.05 | - |
Net Income |
-10.9 M | -2.7 M | -4.97 M | -3.99 M | 2 M | -3.43 M | -922 K | -1.6 M | -1.87 M | -1.9 M | -2.25 M | -271 K | -44.4 K | -23.5 K | 271 K | - |
Revenue |
27.4 M | 32.5 M | 40.6 M | 44.3 M | 47.8 M | 53.4 M | 62.6 M | 64.4 M | 35.8 M | 30.4 M | 29.1 M | 27.4 M | 29.5 M | 31.7 M | 32.7 M | - |
Cost of Revenue |
21.4 M | 24.9 M | 30.5 M | 33.7 M | 34.9 M | 38.3 M | 43.4 M | 44 M | 24.2 M | 20.1 M | 20 M | 17.4 M | 18.5 M | 19.7 M | 20.2 M | - |
Gross Profit |
6.01 M | 7.63 M | 10.2 M | 10.7 M | 12.9 M | 15.1 M | 19.2 M | 20.4 M | 11.5 M | 10.4 M | 9.07 M | 10 M | 11.1 M | 11.9 M | 12.5 M | - |
Operating Income |
-2.45 M | -2.27 M | -4.85 M | -4.76 M | -3.76 M | -2.99 M | -796 K | -1.25 M | -1.67 M | -1.69 M | -1.09 M | -186 K | 105 K | 26.4 K | 670 K | - |
Interest Expense |
410 K | 418 K | 118 K | 148 K | 216 K | 436 K | 512 K | -428 K | -278 K | -289 K | -331 K | -232 K | -261 K | -262 K | -294 K | - |
EBITDA |
-1.97 M | -1.59 M | -4.13 M | -4.02 M | -2.91 M | -1.26 M | 815 K | 61 K | -1.34 M | -1.38 M | -691 K | 395 K | 658 K | 475 K | 1.12 M | - |
Operating Expenses |
- | - | - | - | - | 18.1 M | 20 M | 21.7 M | 13.2 M | 12 M | 10.2 M | 10.2 M | 11 M | 11.9 M | 11.8 M | - |
General and Administrative Expenses |
8.46 M | 9.91 M | 15 M | 15.4 M | 16.6 M | 18.1 M | 20 M | 20.5 M | 12.1 M | 11 M | 9.23 M | 9.21 M | 9.86 M | 10.5 M | 10.4 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Dynatronics Corporation
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
13 M | 8.79 M | 10.6 M | 7.26 M | 5.89 M | 7.26 M | 5.89 M | 4.52 M | 4.26 M | 4.04 M | 3.93 M | 3.79 M | 3.71 M | 3.64 M | 3.59 M | 17.7 M | 17.6 M | 17.6 M | 15.8 M | 14.6 M | 14.1 M | 14.6 M | 14.1 M | 9.02 M | 8.58 M | 9.02 M | 8.31 M | 8.19 M | 8.16 M | 8.19 M | 8.16 M | 5.74 M | 4.75 M | 5.74 M | 4.75 M | 2.88 M | 2.84 M | 2.86 M | 2.84 M | 2.67 M | 2.64 M | 2.67 M | 2.64 M | 2.52 M | 2.52 M | 2.52 M | 2.52 M | 2.52 M | 2.52 M | 2.52 M | 2.52 M | 2.54 M | 2.54 M | 2.54 M | 12.7 M | 2.56 M | 13 M | 12.8 M | 13 M |
Net Income |
-202 K | -999 K | -8.76 M | -775 K | -367 K | -775 K | -367 K | -1.01 M | -331 K | -2.38 M | -1.25 M | -841 K | -506 K | -1.56 M | -1.47 M | -1.44 M | 483 K | -959 K | 118 K | -673 K | -378 K | -906 K | -572 K | -448 K | -68.1 K | -448 K | -68.1 K | -644 K | 129 K | -644 K | 129 K | -1.31 M | 11.6 K | -1.31 M | 11.6 K | -560 K | -375 K | -95.3 K | -286 K | -125 K | -182 K | -125 K | -182 K | -134 K | 40.9 K | -134 K | 40.9 K | 44.1 K | -108 K | 44.1 K | -108 K | 141 K | -51.1 K | 141 K | -51.1 K | 46.3 K | -68.3 K | 46.3 K | -68.3 K |
Revenue |
7.02 M | 6.15 M | - | 7.3 M | 7.6 M | 7.3 M | 7.6 M | 8.15 M | 9.35 M | - | 9.24 M | 10.9 M | 12.1 M | 22.9 M | 10.3 M | 10.5 M | 12.3 M | 22.8 M | 11.5 M | 12 M | 12.1 M | 12 M | 12.1 M | 15.2 M | 16.4 M | 15.2 M | 16.4 M | 15.4 M | 17.1 M | 15.4 M | 16.6 M | 18.1 M | 12.8 M | 30.9 M | 7.72 M | 8.71 M | 8.16 M | 8.71 M | 8.16 M | 7.47 M | 7.4 M | 7.47 M | 7.4 M | 7.3 M | 7.22 M | 7.3 M | 7.22 M | 7.15 M | 7.06 M | 7.15 M | 7.06 M | 8 M | 7.21 M | 8 M | 7.21 M | 8.28 M | 8 M | 16.3 M | 8.38 M |
Cost of Revenue |
5.29 M | 5.06 M | - | 5.66 M | 5.62 M | 5.66 M | 5.62 M | 6.33 M | 7.05 M | - | 7.03 M | 7.82 M | 8.41 M | 16.2 M | 8.01 M | 8.45 M | 8.64 M | 17.1 M | 8.16 M | 8.63 M | 8.23 M | 8.63 M | 8.23 M | 10.6 M | 11.2 M | 10.6 M | 11.2 M | 10.8 M | 11.5 M | 10.8 M | 11.5 M | 12.3 M | 8.46 M | 12.3 M | 8.46 M | 5.64 M | 5.37 M | 5.64 M | 5.37 M | 4.8 M | 4.89 M | 4.8 M | 4.89 M | 4.84 M | 4.65 M | 4.84 M | 4.65 M | 4.47 M | 4.47 M | 4.47 M | 4.47 M | 4.9 M | 4.5 M | 4.9 M | 4.5 M | 5.06 M | 4.99 M | 5.06 M | 4.99 M |
Gross Profit |
1.73 M | 1.1 M | - | 1.64 M | 1.98 M | 1.64 M | 1.98 M | 1.82 M | 2.31 M | - | 2.21 M | 3.06 M | 3.64 M | 6.71 M | 2.31 M | 2.08 M | 3.66 M | 5.74 M | 3.3 M | 3.34 M | 3.9 M | 3.34 M | 3.9 M | 4.59 M | 5.15 M | 4.59 M | 5.15 M | 4.68 M | 5.55 M | 4.68 M | 5.55 M | 5.77 M | 4.34 M | 5.77 M | 4.34 M | 3.07 M | 2.79 M | 3.07 M | 2.79 M | 2.68 M | 2.51 M | 2.68 M | 2.51 M | 2.46 M | 2.57 M | 2.46 M | 2.57 M | 2.68 M | 2.58 M | 2.68 M | 2.58 M | 3.1 M | 2.71 M | 3.1 M | 2.71 M | 3.21 M | 3 M | 3.21 M | 3 M |
Operating Income |
-88.5 K | -944 K | - | -667 K | -251 K | -667 K | -251 K | -902 K | -239 K | - | -1.22 M | -800 K | -475 K | -1.27 M | -1.44 M | -1.4 M | -432 K | -1.83 M | -600 K | -597 K | -344 K | -597 K | -344 K | -32.2 K | 229 K | -32.2 K | 229 K | -92.8 K | 50.6 K | -92.8 K | 50.6 K | 107 K | 265 K | 107 K | 265 K | -87.4 K | -249 K | -87.4 K | -249 K | -46 K | -110 K | -46 K | -110 K | -151 K | 99.1 K | -151 K | 99.1 K | 123 K | -113 K | 123 K | -113 K | 259 K | -14.5 K | 259 K | -14.5 K | 114 K | -49.1 K | 114 K | -49.1 K |
Interest Expense |
103 K | 95.4 K | - | 108 K | 106 K | 108 K | 106 K | 110 K | 79.7 K | - | 24.4 K | 37.9 K | 31.5 K | 69.4 K | 35.1 K | 40.2 K | 40.1 K | 80.3 K | 62.5 K | 63.6 K | 39.9 K | 63.6 K | 39.9 K | 110 K | 131 K | 110 K | 131 K | 142 K | 121 K | 142 K | 121 K | 104 K | 76.8 K | 104 K | -76.8 K | 63.4 K | -59.5 K | -63.6 K | -59.5 K | -77.3 K | -80.2 K | -77.3 K | -80.2 K | -79.7 K | -48.3 K | -79.7 K | -48.3 K | -56 K | -59.9 K | -56 K | -59.9 K | -66.1 K | -66.8 K | -66.1 K | -66.8 K | -66.4 K | -63.2 K | - | - |
EBITDA |
19.7 K | -572 K | - | - | -95.8 K | -401 K | -95.8 K | - | -73.7 K | - | - | -800 K | -291 K | -906 K | -1.44 M | -1.4 M | -250 K | -1.47 M | -600 K | -597 K | -99.3 K | -159 K | -99.3 K | -32.2 K | 476 K | 463 K | 476 K | -92.8 K | 250 K | 188 K | 181 K | 107 K | 333 K | 291 K | 197 K | -87.4 K | -302 K | -194 K | -302 K | -46 K | -165 K | -157 K | -165 K | -151 K | 9.28 K | -326 K | 9.28 K | 123 K | -220 K | -90.9 K | -220 K | 259 K | -124 K | 476 K | 94.6 K | 114 K | 50 K | 314 K | 50 K |
General and Administrative Expenses |
1.82 M | 2.04 M | - | 2.31 M | 2.23 M | 2.31 M | 2.23 M | 2.72 M | 2.55 M | - | 3.43 M | 3.86 M | 4.12 M | 7.98 M | 3.75 M | 3.48 M | 4.1 M | 7.58 M | 3.91 M | 3.94 M | 4.25 M | 3.94 M | 4.25 M | 4.62 M | 4.92 M | 4.62 M | 4.92 M | 4.77 M | 5.5 M | 4.77 M | 5.5 M | 5.66 M | 4.07 M | 5.11 M | 3.82 M | 2.85 M | 2.76 M | 2.85 M | 2.76 M | 2.47 M | 2.36 M | 2.47 M | 2.36 M | 2.38 M | 2.25 M | 2.38 M | 2.25 M | 2.32 M | 2.38 M | 2.32 M | 2.38 M | 2.57 M | 2.46 M | 2.57 M | 2.46 M | 2.69 M | 2.69 M | 2.69 M | 2.69 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Main types of financial statements Dynatronics Corporation DYNTFinancial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.
- Income Statement
Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability. - Balance Sheet
Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
Liabilities — debts and other external sources of financing.
Equity — owners' capital and retained earnings. - Cash Flow Statement
Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
- IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
- GAAP — Generally Accepted Accounting Principles used in the United States.
- RAS — Russian Accounting Standards, used domestically in Russia.
Financial reporting Dynatronics Corporation plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.
In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.
Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.
Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.
Financial statements of other stocks in the Medical devices industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Orthofix Medical
OFIX
|
$ 9.81 | -1.8 % | $ 388 M |  Curacao |
 |
TransMedics Group
TMDX
|
$ 70.74 | -1.83 % | $ 2.4 B |  USA |
 |
Abbott Laboratories
ABT
|
$ 103.7 | 1.17 % | $ 181 B | USA |
 |
Electromed
ELMD
|
$ 26.37 | -1.86 % | $ 218 M | USA |
 |
Align Technology
ALGN
|
$ 154.51 | -0.64 % | $ 11.2 B | USA |
 |
InMode Ltd.
INMD
|
$ 13.97 | -0.57 % | $ 903 M |  Israel |
 |
Nevro Corp.
NVRO
|
- | - | $ 217 M | USA |
 |
Inspire Medical Systems
INSP
|
$ 71.11 | -2.13 % | $ 2.09 B | USA |
 |
Apyx Medical Corporation
APYX
|
$ 2.37 | -1.66 % | $ 97.4 M | USA |
 |
IRIDEX Corporation
IRIX
|
$ 0.75 | -2.18 % | $ 12.7 M | USA |
 |
IRadimed Corporation
IRMD
|
$ 85.82 | -2.08 % | $ 1.09 B | USA |
 |
Accuray Incorporated
ARAY
|
$ 0.13 | -2.91 % | $ 15.9 M | USA |
 |
Aethlon Medical
AEMD
|
$ 5.05 | -2.7 % | $ 3.4 M | USA |
 |
Venus Concept
VERO
|
- | - | $ 726 K | USA |
 |
LENSAR
LNSR
|
$ 6.07 | 0.83 % | $ 72.6 M | USA |
 |
Alphatec Holdings
ATEC
|
$ 11.11 | -2.2 % | $ 1.67 B | USA |
 |
Eargo
EAR
|
- | - | $ 10.2 M | USA |
 |
Medtronic PLC
MDT
|
$ 95.41 | -1.18 % | $ 122 B | USA |
 |
Sientra
SIEN
|
- | -16.59 % | $ 10.3 M | USA |
 |
AxoGen
AXGN
|
$ 38.06 | 3.76 % | $ 1.75 B | USA |
 |
Silk Road Medical, Inc
SILK
|
- | - | $ 1.07 B | USA |
 |
Myomo
MYO
|
$ 1.21 | -0.82 % | $ 50.6 M | USA |
 |
Surgalign Holdings
SRGA
|
- | -32.98 % | $ 1.68 M | USA |
 |
ShockWave Medical
SWAV
|
- | - | $ 12.3 B | USA |
 |
Bio-Rad Laboratories
BIO
|
$ 369.95 | 1.68 % | $ 10.1 B | USA |
 |
Abiomed
ABMD
|
- | - | $ 17.2 B | USA |
 |
Titan Medical
TMDI
|
- | -26.32 % | $ 19.6 M |  Canada |
 |
Natus Medical Incorporated
NTUS
|
- | 1.94 % | $ 1.05 B | USA |
 |
Cardiovascular Systems
CSII
|
- | 0.15 % | $ 844 M | USA |
 |
Outset Medical
OM
|
$ 4.1 | -1.68 % | $ 62.4 K | USA |
 |
Bruker Corporation
BRKR
|
$ 57.59 | 0.49 % | $ 8.74 B | USA |
 |
Boston Scientific Corporation
BSX
|
$ 45.69 | -0.7 % | $ 67.6 B | USA |
 |
Inari Medical
NARI
|
- | - | $ 4.23 B | USA |
 |
Allied Healthcare Products
AHPI
|
- | 3.58 % | $ 2.21 M | USA |
 |
PAVmed
PAVM
|
$ 2.17 | 5.85 % | $ 1.45 M | USA |
 |
Insulet Corporation
PODD
|
$ 149.01 | 0.6 % | $ 10.5 B | USA |
 |
Profound Medical Corp.
PROF
|
$ 5.56 | -3.47 % | $ 168 M | Canada |
 |
AVITA Medical
RCEL
|
$ 15.51 | 0.58 % | $ 432 M |  Australia |
 |
Avinger
AVGR
|
- | -20.74 % | $ 369 K | USA |
 |
Apollo Endosurgery
APEN
|
- | - | $ 475 M | USA |
 |
NuVasive
NUVA
|
- | - | $ 2.07 B | USA |
 |
Butterfly Network
BFLY
|
$ 6.76 | -0.81 % | $ 1.67 B | USA |
 |
ClearPoint Neuro
CLPT
|
$ 9.14 | -1.19 % | $ 259 M | USA |
 |
Sintx Technologies
SINT
|
$ 1.58 | -3.66 % | $ 4.38 M | USA |
 |
CONMED Corporation
CNMD
|
$ 49.25 | -0.11 % | $ 1.53 B | USA |
 |
Smith & Nephew plc
SNN
|
$ 30.83 | -0.11 % | $ 26.7 B |  Britain |
 |
Sensus Healthcare
SRTS
|
$ 2.95 | 1.55 % | $ 48.2 M | USA |
 |
Cytosorbents Corporation
CTSO
|
$ 5.27 | -12.31 % | $ 328 M | USA |
 |
Axonics Modulation Technologies
AXNX
|
- | - | $ 3.31 B | USA |
 |
ThermoGenesis Holdings
THMO
|
- | -25.84 % | $ 171 K | USA |